$17.70
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Mizuho Raises Price Target on Amylyx Pharmaceuticals to $24 From $21, Keeps Outperform Rating
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Overview
52-week range
$4.76
$19
93% of range
Avg surprise (last 3)
-2.2%
Avg reaction (last 2)
-5.7%
0% positive
Latest IV / EM
198%
EM ±45.2% · $18 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.37 | $-0.34 | -8.8% | +11.9% | -5.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.37 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.46 | $-0.44 | -4.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.42 | $-0.45 | +6.7% | — | -6.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.07 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.07 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.75 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.30 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.31 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.36 | -$0.46 | +21.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $0 | $0 | $0 | — | $0 | $8,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-44M | — | $-36M | $-43M | $-38M | — | $-76M | $-76M |
| Net income | $-41M | — | $-34M | $-41M | $-36M | — | $-73M | $-73M |
| EPS (diluted) | $-0.37 | — | $-0.37 | $-0.46 | $-0.42 | — | $-1.07 | $-1.07 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $229M | $227M | $225M | $58M | $60M | $77M | $72M | $75M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $285M | $324M | $353M | $187M | $216M | $189M | $245M | $327M |
| Total assets | $294M | $333M | $363M | $195M | $220M | $194M | $251M | $332M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $20M | $27M | $31M | $27M | $18M | $29M | $55M | $71M |
| Total equity | $273M | $305M | $332M | $168M | $201M | $165M | $196M | $261M |